Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 32

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 32
---
 of cash made to holders of ordinary shares or ADSs and (d) the placement agent warrants have a term of five years from the commencement of the sales pursuant to this offering. See “Plan of Distribution”. S - 17 PLAN OF DISTRIBUTION Pursuant to an engagement agreement dated July 24, 2024, as amended on December 30, 2024, we have engaged H.C. Wainwright & Co., LLC, or the placement agent, to act as our exclusive placement agent in connection with this offering of our ADSs and warrants pursuant to this prospectus supplement and accompanying prospectus. Under the terms of the engagement agreement, the placement agent has agreed to be our exclusive placement agent, on a reasonable best efforts basis, in connection with the issuance and sale by us of our ADSs in this takedown from our shelf registration statement. The terms of this offering were subject to market conditions and negotiations between us, the placement agent and prospective investors. The engagement agreement does not give rise to any commitment by the placement agent to purchase any of our securities, and the placement agent will have no authority to bind us by virtue of the engagement agreement. Further, the placement agent does not guarantee that it will be able to raise new capital in any prospective offering. We have entered into a securities purchase agreement directly with investors in connection with this offering, and we will only sell our securities offered hereby to investors who have entered into the securities purchase agreement. We expect to deliver the ADSs and the warrants being offered pursuant to this prospectus supplement and the accompanying prospectus on or about January 7, 2025, subject to satisfaction of certain customary closing conditions. We have agreed to pay the placement agent a total cash fee equal to 7.0% of the gross proceeds of this offering. We will also pay the placement agent a management fee equal to 1.0% of the gross proceeds raised in this offering, a non-accountable expense allowance of $25,000, $40,000 for accountable expenses and clearing fees of $15,950. We estimate our total expenses associated with the offering, excluding placement agent fees and expenses, will be approximately $0.2 million. In addition, we agreed to issue warrants to the placement agent to purchase a number of ADSs equal to 5% of the aggregate number of ADSs sold to the investors in this offering, or 2,500,000 ADSs. The placement agent warrants will have an exercise price of $0.25 per ADS, which is